BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chin JL, Pavlides M, Moolla A, Ryan JD. Non-invasive Markers of Liver Fibrosis: Adjuncts or Alternatives to Liver Biopsy? Front Pharmacol. 2016;7:159. [PMID: 27378924 DOI: 10.3389/fphar.2016.00159] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 4.7] [Reference Citation Analysis]
Number Citing Articles
1 Fateen W, Ryder SD. Screening for hepatocellular carcinoma: patient selection and perspectives. J Hepatocell Carcinoma. 2017;4:71-79. [PMID: 28553624 DOI: 10.2147/jhc.s105777] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
2 Zehra M, Curry JC, Pillai SS, Lakhani HV, Edwards CE, Sodhi K. Elucidating Potential Profibrotic Mechanisms of Emerging Biomarkers for Early Prognosis of Hepatic Fibrosis. Int J Mol Sci 2020;21:E4737. [PMID: 32635162 DOI: 10.3390/ijms21134737] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
3 Rewisha E, Salman T, Alhaddad O, Raia GA, Naguib M, Rashad S, Abdelfattah A, Metwally K, Abdelsameea E. Hyaluronic acid as a potential marker for assessment of fibrosis regression after direct acting antiviral drugs in chronic hepatitis C patients. Clin Exp Hepatol 2021;7:320-7. [PMID: 34712835 DOI: 10.5114/ceh.2021.109293] [Reference Citation Analysis]
4 Hansen JF, Juul Nielsen M, Nyström K, Leeming DJ, Lagging M, Norkrans G, Brehm Christensen P, Karsdal M. PRO-C3: a new and more precise collagen marker for liver fibrosis in patients with chronic hepatitis C. Scand J Gastroenterol 2018;53:83-7. [PMID: 29069995 DOI: 10.1080/00365521.2017.1392596] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
5 Thomaides-Brears HB, Lepe R, Banerjee R, Duncker C. Multiparametric MR mapping in clinical decision-making for diffuse liver disease. Abdom Radiol (NY). 2020;45:3507-3522. [PMID: 32761254 DOI: 10.1007/s00261-020-02684-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
6 Marjot T, Moolla A, Cobbold JF, Hodson L, Tomlinson JW. Nonalcoholic Fatty Liver Disease in Adults: Current Concepts in Etiology, Outcomes, and Management. Endocr Rev. 2020;41. [PMID: 31629366 DOI: 10.1210/endrev/bnz009] [Cited by in Crossref: 30] [Cited by in F6Publishing: 35] [Article Influence: 30.0] [Reference Citation Analysis]
7 Rinella M, Dufour JF, Anstee QM, Goodman Z, Younossi Z, Harrison SA, Loomba R, Sanyal AJ, Bonacci M, Trylesinski A, Natha M, Shringarpure R, Granston T, Venugopal A, Ratziu V. Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study. J Hepatol 2021:S0168-8278(21)02177-2. [PMID: 34793868 DOI: 10.1016/j.jhep.2021.10.029] [Reference Citation Analysis]
8 Parikh P, Ryan JD, Tsochatzis EA. Fibrosis assessment in patients with chronic hepatitis B virus (HBV) infection. Ann Transl Med. 2017;5:40. [PMID: 28251119 DOI: 10.21037/atm.2017.01.28] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 7.4] [Reference Citation Analysis]
9 Berzigotti A, França M, Martí-aguado D, Martí-bonmatí L. Cuantificación de la fibrosis hepática mediante biomarcadores de imagen. Radiología 2018;60:74-84. [DOI: 10.1016/j.rx.2017.09.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
10 Salah MM, Ashour AA, Abdelghany TM, Abdel-Aziz AH, Salama SA. Pirfenidone alleviates concanavalin A-induced liver fibrosis in mice. Life Sci 2019;239:116982. [PMID: 31639402 DOI: 10.1016/j.lfs.2019.116982] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
11 Mckenna-barry MT, Ryan JD. Studies on non-alcoholic fatty liver disease should stratify by disease severity. BMJ. [DOI: 10.1136/bmj.l6495] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
12 Qi M, Chen Y, Zhang GQ, Meng YJ, Zhao FL, Wang J, Ma J. Clinical significance of preoperative liver stiffness measurements in primary HBV-positive hepatocellular carcinoma. Future Oncol 2017;13:2799-810. [PMID: 29189041 DOI: 10.2217/fon-2017-0281] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
13 McDyre BC, AbdulHameed MDM, Permenter MG, Dennis WE, Baer CE, Koontz JM, Boyle MH, Wallqvist A, Lewis JA, Ippolito DL. Comparative Proteomic Analysis of Liver Steatosis and Fibrosis after Oral Hepatotoxicant Administration in Sprague-Dawley Rats. Toxicol Pathol 2018;46:202-23. [PMID: 29378501 DOI: 10.1177/0192623317747549] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
14 Pan S, Wang XQ, Guo QY. Quantitative assessment of hepatic fibrosis in chronic hepatitis B and C: T1 mapping on Gd-EOB-DTPA-enhanced liver magnetic resonance imaging. World J Gastroenterol 2018; 24(18): 2024-2035 [PMID: 29760545 DOI: 10.3748/wjg.v24.i18.2024] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
15 Cordie A, Salama A, El-Sharkawy M, El-Nahaas SM, Khairy M, Elsharkawy A, Hassany M, Esmat G. Comparing the efficiency of Fib-4, Egy-score, APRI, and GUCI in liver fibrosis staging in Egyptians with chronic hepatitis C. J Med Virol 2018;90:1106-11. [PMID: 29476628 DOI: 10.1002/jmv.25064] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
16 Baudi I, Inoue T, Tanaka Y. Novel Biomarkers of Hepatitis B and Hepatocellular Carcinoma: Clinical Significance of HBcrAg and M2BPGi. Int J Mol Sci. 2020;21. [PMID: 32023902 DOI: 10.3390/ijms21030949] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
17 Sherman KE, Abdel-Hameed EA, Ehman RL, Rouster SD, Campa A, Martinez SS, Huang Y, Zarini GG, Hernandez J, Teeman C, Tamargo J, Liu Q, Mandler R, Baum MK. Validation and Refinement of Noninvasive Methods to Assess Hepatic Fibrosis: Magnetic Resonance Elastography Versus Enhanced Liver Fibrosis Index. Dig Dis Sci 2020;65:1252-7. [PMID: 31468264 DOI: 10.1007/s10620-019-05815-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
18 Moscoso CG, Steer CJ. "Let my liver rather heat with wine" - a review of hepatic fibrosis pathophysiology and emerging therapeutics. Hepat Med 2019;11:109-29. [PMID: 31565001 DOI: 10.2147/HMER.S213397] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
19 Takaya H, Kawaratani H, Tsuji Y, Nakanishi K, Saikawa S, Sato S, Sawada Y, Kaji K, Okura Y, Shimozato N, Kitade M, Akahane T, Moriya K, Namisaki T, Mitoro A, Matsumoto M, Fukui H, Yoshiji H. von Willebrand factor is a useful biomarker for liver fibrosis and prediction of hepatocellular carcinoma development in patients with hepatitis B and C. United European Gastroenterol J. 2018;6:1401-1409. [PMID: 30386613 DOI: 10.1177/2050640618779660] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
20 Wijarnpreecha K, Thongprayoon C, Scribani M, Ungprasert P, Cheungpasitporn W. Noninvasive fibrosis markers and chronic kidney disease among adults with nonalcoholic fatty liver in USA. Eur J Gastroenterol Hepatol. 2018;30:404-410. [PMID: 29215435 DOI: 10.1097/meg.0000000000001045] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
21 Yokoyama H, Masaki T, Inoue I, Nakamura M, Mezaki Y, Saeki C, Oikawa T, Saruta M, Takahashi H, Ikegami M, Hano H, Ikejima K, Kojima S, Matsuura T. Histological and biochemical evaluation of transforming growth factor-β activation and its clinical significance in patients with chronic liver disease. Heliyon 2019;5:e01231. [PMID: 30815603 DOI: 10.1016/j.heliyon.2019.e01231] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
22 Ebrahim AE, Shehata MAH, Abou-saif S, Hamisa MF, Abd-elsalam S, Yousef M. Role of Fibroscan for early detection of hepatocellular carcinoma (HCC) in hepatitis C cirrhotic patients. Egypt J Radiol Nucl Med 2020;51. [DOI: 10.1186/s43055-020-00258-3] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
23 Ding K, Liu M, Wei X, Huang R, Chen J, Lu S, Wang D, Lu W. Comparison of MR-PWI quantitative and semi-quantitative parameters for the evaluation of liver fibrosis. BMC Med Imaging 2021;21:8. [PMID: 33407215 DOI: 10.1186/s12880-020-00539-3] [Reference Citation Analysis]
24 Da BL, Surana P, Takyar V, Kleiner DE, Heller T, Koh C. Vibration-controlled transient elastography for the detection of cirrhosis in chronic hepatitis D infection. J Viral Hepat 2020;27:428-36. [PMID: 31742822 DOI: 10.1111/jvh.13235] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
25 Marri UK, Das P, Shalimar, Kalaivani M, Srivastava DN, Madhusudhan KS. Noninvasive Staging of Liver Fibrosis Using 5-Minute Delayed Dual-Energy CT: Comparison with US Elastography and Correlation with Histologic Findings. Radiology 2021;298:600-8. [PMID: 33399510 DOI: 10.1148/radiol.2021202232] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
26 Gatselis NK, Zachou K, Giannoulis G, Gabeta S, Norman GL, Dalekos GN. Serum Cartilage Oligomeric Matrix Protein and Golgi Protein-73: New Diagnostic and Predictive Tools for Liver Fibrosis and Hepatocellular Cancer? Cancers (Basel) 2021;13:3510. [PMID: 34298722 DOI: 10.3390/cancers13143510] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
27 Gouvêa AFTB, Filho RC, Machado DM, Bononi do Carmo F, Beltrão SV, Sampaio L, de Moraes-Pinto MI, Succi RCM. Assessment of liver disease by non-invasive methods in perinatally infected Brazilian adolescents and young adults living with Human Immunodeficiency Virus (HIV). Braz J Infect Dis 2021;25:101589. [PMID: 34147474 DOI: 10.1016/j.bjid.2021.101589] [Reference Citation Analysis]
28 Ryan JD, Armitage AE, Cobbold JF, Banerjee R, Borsani O, Dongiovanni P, Neubauer S, Morovat R, Wang LM, Pasricha SR. Hepatic iron is the major determinant of serum ferritin in NAFLD patients. Liver Int. 2017; Epub ahead of print. [PMID: 28679028 DOI: 10.1111/liv.13513] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 6.6] [Reference Citation Analysis]
29 Dolman GE, Koffas A, Mason WS, Kennedy PT. Why, who and when to start treatment for chronic hepatitis B infection. Curr Opin Virol. 2018;30:39-47. [PMID: 29655092 DOI: 10.1016/j.coviro.2018.03.006] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
30 Dhyani M, Xiang F, Li Q, Chen L, Li C, Bhan AK, Anthony B, Grajo JR, Samir AE. Ultrasound Shear Wave Elastography: Variations of Liver Fibrosis Assessment as a Function of Depth, Force and Distance from Central Axis of the Transducer with a Comparison of Different Systems. Ultrasound Med Biol 2018;44:2209-22. [PMID: 30143339 DOI: 10.1016/j.ultrasmedbio.2018.07.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]